Vanda Prescription drugs (VNDA) shares soared 5.8% within the final buying and selling session to shut at $21.51. The transfer was backed by stable quantity with way more shares altering palms than in a traditional session. This compares to the inventory’s 14.2% acquire over the previous 4 weeks.
Shares surged as traders are optimistic on the prospects of Hetlioz for the indication of nighttime sleep disturbances in sufferers with Smith-Magenis Syndrome. The pipeline progress has been encouraging too.
This biopharmaceutical firm is anticipated to submit quarterly earnings of $0.17 per share in its upcoming report, which represents a year-over-year change of +6.3%. Revenues are anticipated to be $71 million, up 14.1% from the year-ago quarter.
Earnings and income development expectations actually give sense of the potential power in a inventory, however empirical analysis exhibits that traits in earnings estimate revisions are strongly correlated with near-term inventory worth actions.
For Vanda, the consensus EPS estimate for the quarter has remained unchanged during the last 30 days. And a inventory’s worth often would not hold shifting greater within the absence of any development in earnings estimate revisions. So, ensure that to regulate VNDA going ahead to see if this current bounce can flip into extra power down the street.
The inventory at present carries a Zacks Rank 3 (Maintain). You possibly can see the entire record of right this moment’s Zacks Rank #1 (Sturdy Purchase) shares right here >>>>
Click on to get this free report
Vanda Prescription drugs Inc. (VNDA): Free Inventory Evaluation Report
To learn this text on Zacks.com click on right here.
Zacks Funding Analysis
The views and opinions expressed herein are the views and opinions of the creator and don’t essentially mirror these of Nasdaq, Inc.